Sebelipase alfa
From Wikipedia, the free encyclopedia
Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D).[6][7] It is administered via intraveneous infusion.[5] It was approved for medical use in the European Union and in the United States in 2015.[8][6][5][7]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Kanuma |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 0.1 hours |
Identifiers | |
DrugBank | |
ChemSpider |
|
KEGG |
Close